Curated News
By: NewsRamp Editorial Staff
August 11, 2025
Nutriband CEO Steps Down Temporarily for Irish Presidential Bid
TLDR
- Nutriband's CEO steps down temporarily, with the chairman taking over to advance AVERSA Fentanyl, a groundbreaking abuse-deterrent opioid patch with potential sales up to $200 million.
- Nutriband Inc. transitions leadership as CEO pursues political candidacy, with the chairman ensuring progress towards the 2026 NDA filing for AVERSA Fentanyl, protected by patents in 46 countries.
- AVERSA Fentanyl by Nutriband aims to reduce opioid abuse and accidental exposure, marking a significant step forward in public health and safety.
- Nutriband's AVERSA technology could revolutionize pain management by deterring abuse of fentanyl patches, with a unique approach to preventing misuse and accidental exposure.
Impact - Why it Matters
This news is significant as it highlights Nutriband's innovative approach to addressing the opioid crisis with its AVERSA Fentanyl patch, a potential game-changer in pain management. The temporary leadership transition underscores the company's resilience and commitment to its mission, ensuring continued progress towards bringing safer pharmaceutical options to market. For investors and the healthcare sector, Nutriband's developments represent a critical step forward in combating drug abuse and enhancing patient safety.
Summary
Nutriband Inc. (NASDAQ: NTRB), a leader in transdermal pharmaceutical products, has announced a temporary leadership change as CEO Gareth Sheridan steps aside to pursue candidacy in the Irish Presidential election. During his three-month leave, Co-Founder and Chairman Serguei Melnik will take over as CEO, steering the company towards its ambitious 2026 NDA filing target. The company's focus remains on advancing AVERSA Fentanyl, an innovative abuse-deterrent opioid patch, which has recently garnered FDA attention with a meeting request. This groundbreaking product, protected by patents in 46 countries, aims to revolutionize pain management by preventing misuse and accidental exposure, with projected U.S. sales between $80 million and $200 million. For more details, visit the full press release.
Nutriband's commitment to developing safer pharmaceutical solutions is underscored by its AVERSA technology, designed to mitigate the risks associated with drugs of abuse. The company's strategic direction and product pipeline, including the AVERSA Fentanyl patch, highlight its potential to make significant impacts in global medical markets. Investors and stakeholders can stay updated through the company's newsroom at https://ibn.fm/NTRB.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband CEO Steps Down Temporarily for Irish Presidential Bid
